R.p.scherer Technologies, Inc.

Pfizer Corporation

Cornell University

Schering Corporation

Beth Israel Deaconess Medical Center, Inc.

Chao Bai Huang

David Rabuka

Yun Cheol Kim

Penelope M Drake

Lioudmila Tchistiakova

Linda Masat

Toshihiko Takeuchi

Kimberly Ann Marquette

Lewis C Cantley

Lidia Mosyak

Isaac J Rondon

Eric M Bennett

Sumant Ramachandra

Chin-Yi Huang

Irina Apostolou

Walter Robert Bishop

Seema Kantak

Brooke M Emerling

Stephen P Soltoff

Cindy M Hodakoski

Brian Gaither Bates

Edward Christian Rosfjord

Georgios Poulogiannis

Hui Liu

The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

CDCP1 antibodies and antibody drug conjugates

Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) heavy chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig heavy chain polypeptide. An fGly-modified Ig heavy chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig heavy chain polypeptides, fGly-modified Ig heavy chain polypeptides, and antibody conjugates, as well as methods of use of same.

Antibody conjugates and methods of making and using the same

Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) light chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig light chain polypeptide. An fGly-modified Ig light chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig light chain polypeptides, fGly-modified Ig light chain polypeptides, and antibody conjugates, as well as methods of use of same.

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Fully human anti-VEGF antibodies and methods of using

Growing community of inventors

San Leandro, CA, United States of America

Chao Bai Huang